NCT03248037View on ClinicalTrials.gov

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

July 9, 2019

Study Completion Date

July 9, 2019

Conditions
Fuchs' Endothelial DystrophyBullous Keratopathy
Interventions
DRUG

Netarsudil

netarsudil opthalmic solution 0.02%

DRUG

Placebo

Placebo eye drops

Trial Locations (1)

46260

Price Vision Group, Indianapolis

Sponsors
All Listed Sponsors
lead

Cornea Research Foundation of America

OTHER